Today: 1 May 2026
Browse Category

Pharmaceutical Industry 2 October 2025 - 17 November 2025

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Novo Nordisk slashed the self-pay price of Wegovy and most Ozempic doses from $499 to $349 per month, effective Nov. 17, 2025. New patients can access starter doses for $199 monthly for two months. The move follows White House deals expanding Medicare and Medicaid coverage for obesity drugs and comes as telehealth firms launch competing $199 offers.
17 November 2025
·
Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock shares surged 26% to $37.98 after an FDA meeting on its SMA therapy and the launch of a $200 million at-the-market stock offering. The company reported a Q3 2025 net loss of $102.2 million, up from $64.5 million a year earlier, with no revenue as it prepares for a potential U.S. launch in 2026. Trading volume topped 2.7 million shares.
14 November 2025
····
Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics shares rose about 22% after the FDA accepted its resubmitted Biologics License Application for ONS‑5010/LYTENAVA as a treatment for wet AMD, setting a PDUFA review date of December 31, 2025. The FDA classified the filing as a complete, Class 1 response, triggering a 60-day review. The move follows an August rejection over insufficient efficacy data. ONS‑5010/LYTENAVA is already approved in the EU and UK.
13 November 2025
··
Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Day One Biopharmaceuticals will acquire Mersana Therapeutics in a deal valued at up to $285 million, offering $25 per share in cash plus contingent value rights up to $30.25 per share. Mersana’s board and major holders support the agreement. MRSN shares jumped as much as 200% pre-market. Halper Sadeh LLC launched a shareholder fairness investigation.
13 November 2025
···
Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto said it acquired Damora Therapeutics and raised $284.9 million in an oversubscribed private placement, extending its cash runway into 2029. The moves shift Galecto’s focus to mutant calreticulin therapies for myeloproliferative neoplasms. GLTO shares surged about 285% in pre-market trading. No shareholder vote was required for the acquisition.
10 November 2025
··
Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals shares jumped over 30% to around $38 on Nov. 5, 2025, after reporting Q3 revenue of $69.5 million, up 25% year-over-year. Net income reached $27.9 million, and the company raised its 2025 revenue guidance to $285–$290 million. Product sales, led by Tavalisse, surged 65%. Rigel also announced new clinical milestones and ongoing global partnerships.
5 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer shares traded near $24.60 on Nov. 4, 2025, down about 8–9% year-to-date and over 60% from their 2021 peak. Q3 adjusted earnings beat forecasts at $0.87 per share, but revenue missed slightly at $16.65 billion. Pfizer raised its full-year profit outlook and reaffirmed revenue guidance. The company is locked in a takeover battle with Novo Nordisk for obesity drug developer Metsera.
4 November 2025
·····
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kimberly-Clark agreed to acquire Kenvue for $48.7 billion on Nov. 3, 2025, a 46% premium to its prior close. Kenvue shares surged nearly 20% on the news, while Kimberly-Clark stock dropped 13%. The deal follows a turbulent year for Kenvue, including a CEO ouster, falling sales, and litigation over Tylenol safety claims. Kenvue posted $15 billion in 2025 revenue and maintained gross margins near 59%.
4 November 2025
···
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis reported 2024 revenue of $9.3 billion, up 9% from 2023, with gross margins near 72% and net profit margin around 29%. Shares traded at $130–$135 in November 2025, down from a 52-week high of $180. The company raised its dividend by 15% to $2.00 per share. Analysts’ average 12-month target is $188, though some issued downgrades in late 2025 amid slowing growth.
4 November 2025
··
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical, now Avenir Wellness Solutions (AVRW), closed at $3.78 on Oct. 31, up 30.8% in one day and more than doubling over two weeks. The rally follows a settlement converting major debt to equity and anticipation of Nov. 18 earnings. The company rebranded in 2023 and focuses on wellness products. Technical signals warn of high volatility and potential pullback after the surge.
3 November 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Rani Therapeutics shares closed at $2.20 on Oct. 31, up 51.7% for the day, following a $1.09 billion collaboration deal with Chugai Pharma and a $60.3 million equity raise. Trading volume surged, with nearly 172 million shares changing hands Oct. 20. Founder Mir Imran bought 2.08 million shares Oct. 27. Wall Street analysts now rate RANI a “Strong Buy” with average price targets near $10–11.
31 October 2025
··
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb reported Q3 adjusted EPS of $1.63 on $12.2 billion revenue, beating estimates, and raised its 2025 outlook. Shares rebounded 3–4% after hitting a 52-week low, with dividend yield now near 5.5%. New drugs like Opdivo and Eliquis outperformed, offsetting a sharp Revlimid decline. The company acquired Orbital Therapeutics and launched schizophrenia drug Cobenfy, posting $62 million in early sales.
30 October 2025
··
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna shares closed at $299.12 on Oct 29, down 3% for the week, before rising to $303 in Oct 30 premarket trading. The company reported Q3 revenue of $69.7 billion and net income of $1.87 billion, beating forecasts and reaffirming its full-year outlook. Cigna launched a new pharmacy benefit model and Evernorth invested $3.5 billion in Shields Health. Analyst consensus remains bullish with a $370–$377 price target.
30 October 2025
···
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics shares plunged nearly 45% Monday after the company halted two Phase 3 trials of its CRISPR therapy NTLA-2001 due to a severe liver injury in a patient. The stock dropped from about $19 to the low teens, with CRISPR Therapeutics also falling 10%. Intellia paused dosing and enrollment following the Grade 4 liver event and is consulting regulators on next steps.
27 October 2025
···
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Novartis will acquire Avidity Biosciences for $72 per share in cash, a deal valuing Avidity at $12 billion and marking a 46% premium over its last close. The transaction, announced Oct. 26, 2025, is expected to close in the first half of 2026. Before closing, Avidity will spin off its early-stage cardiology programs into a new company, with shareholders receiving both cash and SpinCo shares.
27 October 2025
·····
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead shares closed near $123 on Oct. 17, 2025, up 4.2% and close to 52-week highs, after extending Biktarvy’s U.S. exclusivity to 2036 and securing a CDC endorsement for Yeztugo. Q2 earnings beat forecasts, prompting raised guidance and analyst upgrades. Gilead is set to present positive Phase 3 Trodelvy data at ESMO and is expanding cell therapy with a $350M Interius BioTherapeutics deal.
18 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Rani Therapeutics shares surged 248% to close at $1.64 on Oct. 17 after announcing a collaboration with Chugai Pharmaceutical worth up to $1.08 billion. The deal includes $10 million upfront and up to $175 million in milestones for the first drug. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. The company’s RaniPill technology delivers injectable drugs via oral capsules.
18 October 2025
···
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue shares plunged 13% Thursday to a record low near $14 after news of U.K. lawsuits over Johnson’s Baby Powder, representing 3,000 claimants and potential £1 billion in damages. The stock is down about 34% year-to-date and nearly 40% below its IPO price. Wall Street cut price targets and Moody’s downgraded its outlook to “negative.” Kenvue’s market cap now stands at roughly $30–31 billion.
17 October 2025
···
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics shares surged over 30% to $89.19 on Oct. 10, 2025, after reports that Johnson & Johnson is in talks to acquire the company. Trading was briefly halted due to volatility. The jump follows positive Phase 2b results for Icotrokinra in ulcerative colitis and recent FDA Breakthrough Therapy Designation for Rusfertide in polycythemia vera.
10 October 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Pfizer shares surged 15% from Sept. 26 to Oct. 1, closing at $27.21 after a major drug-pricing deal with the Trump administration. The agreement, announced Sept. 30, ties U.S. Medicaid prices to those in other wealthy countries in exchange for tariff relief. Pfizer also agreed to buy obesity-drug developer Metsera for $4.9 billion. Market cap stands near $155 billion, with a dividend yield around 6%.
2 October 2025
···
1 … 6 7 8 9

Stock Market Today

  • S&P/TSX composite rises as U.S. tech earnings boost markets
    April 30, 2026, 7:45 PM EDT. The S&P/TSX composite index climbed 645.94 points to 33,964.33 on Thursday, driven by strong earnings from major U.S. tech firms. Alphabet's 10% rally followed a profit nearly double analysts' expectations, highlighting AI investment as a key growth driver. U.S. stock markets also advanced, with the Dow up 790.33 points and the Nasdaq rising 219.07 points. Investor optimism grows amid steady central bank rates in Canada and the U.S., despite ongoing Middle East tensions affecting oil trade routes and prices. Crude oil dipped slightly to around $105 per barrel, with demand concerns above $110. The Canadian dollar strengthened slightly to 73.40 cents US. Analysts note AI spending by tech giants now exceeds $700 billion, signaling a significant tech growth cycle.

Latest article

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

30 April 2026
Nvidia shares dropped 4.6% to $199.57 Thursday as investors reacted to Alphabet and Amazon expanding sales of their own AI chips. Alphabet reported Google Cloud revenue up 63% and began selling TPU chips directly to customers. AMD and Broadcom shares rose 5.1% and 3.0%, respectively. Amazon said its Trainium chip line secured $225 billion in revenue commitments.
Go toTop